Skip to main content
International Journal of Neuropsychopharmacology logoLink to International Journal of Neuropsychopharmacology
. 2016 May 27;19(Suppl 1):39. doi: 10.1093/ijnp/pyw044.653

PT653. Experience using suvorexant to treat delirium

Kodo Fujiwara 1, Shinichi Kohata 1, Hidenori Sumiyoshi 1, Tsutomu Kataoka 1, Osamu Takeshita 1, Jun Omura 1, Junko Kuroda 1
PMCID: PMC5616985

Abstract

Objective: Suvorexant is a sleep aid that acts on the orexin receptor. The current study examined experience using suvorexant to treat delirium in order to determine suvorexant’s efficacy.

Subjects and Methods: Patients who received suvorexant in this Department from January to October 2015 were studied retrospectively. Privacy was considered and subjects were not individually identifiable. Patients consisted of 82 males and 77 females; most patients were in their 70s, although some were in their 80s.

Results: The most prevalent symptom (94 patients) was insomnia, followed by delirium (58 patients) and other complaints (7 patients). Suvorexant was efficacious in treating 84 patients with insomnia (69%). Of the 58 patients who exhibited delirium, most were in their 80s. Suvorexant was efficacious in treating 36 patients with delirium (78%).

Discussion: Suvorexant is a drug to treat insomnia, and there was no evidence of its efficacy in treating delirium. However, the current results revealed that suvorexant is as or more efficacious at treating delirium as it is at treating insomnia. Additional cases need to be assembled in the future to determine if suvorexant is efficacious at treating delirium.


Articles from International Journal of Neuropsychopharmacology are provided here courtesy of Oxford University Press

RESOURCES